NEW HAVEN, Conn., June 2, 2009 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will give a corporate overview and update on the Company's HCV programs at the following upcoming investment conferences:
